AWA
CPRX

Acumen Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Acumen Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9K Sell
920
-16
-2% -$472 0.01% 202
2026
Q1 		$23.2K Hold
936
– – 0.01% 206
2025
Q4 		$21.8K Buy
+936
New +$20.9K 0.01% 208

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acumen Wealth Advisors's CPRX Position: Q2 2026 in Review

Acumen Wealth Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 1.7% in Q2 2026, selling an estimated $472 and leaving 920 shares worth $28.9K. The position accounts for 0.01% of the portfolio, ranked #202.

Acumen Wealth Advisors first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Acumen Wealth Advisors held 920 shares of Catalyst Pharmaceutical worth $28.9K as of Q2 2026.
  • Acumen Wealth Advisors sold 16 Catalyst Pharmaceutical shares in Q2 2026, an estimated $472.
  • Catalyst Pharmaceutical made up 0.01% of Acumen Wealth Advisors's portfolio in Q2 2026, its #202 holding.
  • Acumen Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Acumen Wealth Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.